Articles From: Glaxo Withdraws European Application for Melanoma Treatment to GlaxoSmithKline: Phase 3 Melanoma Study Meets Primary Endpoint


2014/3/26
LONDON--Drug group GlaxoSmithKline PLC (GSK.LN) said Wednesday that it has withdrawn an application to the European Medicines Agency relating to its melanoma treatment Mekinist, also known as trametinib.
Sign-up for Glaxo Withdraws European Application for Melanoma Treatment investment picks
By Sara Sjolin, MarketWatch LONDON (MarketWatch) -- The U.K.'s benchmark stock index retreated from an almost five-month high on Wednesday, as mining firms tracked metals prices lower and GlaxoSmithKline PLC fell after reporting a drop in earnings.
Sign-up for Glaxo, miners pull FTSE 100 from five-month high investment picks
2013/12/20
By Rory Gallivan LONDON--GlaxoSmithKline PLC (GSK.LN) Friday said the U.S. Food and Drug Administration has given its malaria treatment tafenoquine a designation that aims to speed up the approval process for drugs used to treat life-threatening diseases.
Sign-up for Glaxo's Malaria Drug Gets US Breakthrough Therapy Designation investment picks
2014/3/20
By Razak Musah Baba LONDON -- GlaxoSmithKline PLC said Thursday that its MAGE-A3 cancer vaccine hadn't met its first or second co-primary endpoints in its Phase III trial.
Sign-up for GlaxoSmithKline cancer drug suffers setback investment picks
2014/4/4
By Laurie Burkitt BEIJING--
Sign-up for GlaxoSmithKline Cuts Staff in China Amid Probe -- Update investment picks
By Rory Gallivan LONDON--GlaxoSmithKline PLC (GSK.LN) Friday said the European Medicines Agency has recommended marketing authorization for its type 2 diabetes treatment Eperzan.
Sign-up for GlaxoSmithKline Diabetes Treatment Gets Positive EMA Opinion investment picks
2014/2/5
By Hester Plumridge LONDON --
Sign-up for GlaxoSmithKline finally sees full-year sales gain investment picks
2014/4/2
By Ed Ballard GlaxoSmithKline PLC (GSK) Tuesday said it had called a halt to a late-stage trial of a cancer vaccine.
Sign-up for GlaxoSmithKline Halts Late-Stage Trial of Cancer Vaccine investment picks
LONDON--Pharmaceutical giant GlaxoSmithKline PLC (GSK.LN) said late Sunday that, following the voluntary open offer undertaken by its subsidiary, GlaxoSmithKline Pte Ltd, it has increased its stake in its publicly-listed pharmaceuticals subsidiary in India GlaxoSmithKline Pharmaceuticals Ltd.
Sign-up for GlaxoSmithKline Increases Indian Unit Stake to 75% investment picks
2013/12/16
By Gurdev Singh Virk MUMBAI--GlaxoSmithKline Plc (GSK) on Monday floated an open offer to buy an additional 24.33% stake in its Indian unit, GlaxoSmithkline Pharmaceuticals, (500660.BY), with the aim of raising its shareholding to 75%. The offer to shareholders, valued at $1 billion, is being made at a 26% premium over GlaxoSmithKline Pharmaceuticals' closing share price on Friday.
Sign-up for GlaxoSmithKline Issues Open Offer To Up Stake To 75% In India Unit investment picks
2013/10/21
FRANKFURT--The following is a summary of analysts' forecasts for GlaxoSmithKline plc (GSK) third-quarter results, based on a poll of five analysts conducted by Dow Jones Newswires (figures in million pound, EPS, dividend and target price in pence, according to IFRS). Earnings figures are scheduled to be released October 23.
Sign-up for GlaxoSmithKline plc 3Q 2013 -- Forecast investment picks
2014/2/3
FRANKFURT--The following is a summary of analysts' forecasts for GlaxoSmithKline plc (GSK) fourth-quarter results, based on a poll of six analysts conducted by Dow Jones Newswires (figures in million pound, EPS, dividend and target price in pence, according to IFRS). Earnings figures are scheduled to be released February 5.
Sign-up for GlaxoSmithKline plc 4Q 2013 -- Forecast investment picks
- First broadening of influenza-strain protection to occur in more than 30 years PHILADELPHIA , Aug.
Sign-up for GlaxoSmithKline receives FDA approval to ship four-strain (quadrivalent) influenza vaccine to healthcare providers investment picks
2014/3/31
By Ed Ballard LONDON--GlaxoSmithKline PLC (GSK) on Monday detailed disappointing results from a late-stage study of darapladib, a new heart disease drug.
Sign-up for GlaxoSmithKline Reports Disappointing Results for Heart Disease Drug investment picks
By Hester Plumridge LONDON-- GlaxoSmithKline PLC released positive results Wednesday from two late-stage studies on a drug for severe asthma and said it hopes to file for global regulatory approval later this year.
Sign-up for GlaxoSmithKline Reports Positive Results from Asthma Drug Studies -- Update investment picks
LONDON--Pharmaceutical company GlaxoSmithKline PLC (GSK.LN) Wednesday announced positive results from a phase III study of mepolizumab, an investigational drug used for treatment of asthma.
Sign-up for GlaxoSmithKline Reports Positive Results from Study of Asthma Drug investment picks
By Razak Musah Baba LONDON--GlaxoSmithKline PLC (GSK.LN) said Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion recommending marketing authorization for its respiratory drug umeclidinium under the proposed brand name Incruse The research-based pharmaceutical firm said the Agency recommended umeclidinium as a once-daily, maintenance treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease.
Sign-up for GlaxoSmithKline Says Respiratory Drug Gets Positive CHMP Opinion investment picks
2013/12/16
MUMBAI--GlaxoSmithKline Plc (GSK) on Monday floated an open offer to buy an additional 24.33% stake in its Indian unit, GlaxoSmithkline Pharmaceuticals, (500660.BY), with the aim of raising its shareholding to 75%. The offer to shareholders, valued at $1 billion, is being made at a 26% premium over GlaxoSmithKline Pharmaceuticals' closing share price on Friday.
Sign-up for GlaxoSmithKline Seeks To Up Stake In India Unit investment picks
2013/11/20
By Rory Gallivan LONDON--Britain's biggest pharmaceutical company GlaxoSmithKline PLC (GSK.LN) said Wednesday it has agreed to sell 28.2 million shares in South African company Aspen Pharmacare Holdings Ltd.
Sign-up for GlaxoSmithKline Sells Part of Aspen Pharmacare Stake investment picks
2014/3/14
By Ed Ballard and Hester Plumridge LONDON--U.K. pharmaceuticals giant GlaxoSmithKline PLC (GSK.LN) Friday said three late-stage studies into a lung disease drug it developed with San Francisco-based Theravance Inc.(THRX) produced positive results.
Sign-up for GlaxoSmithKline Studies on Lung Disease Drug Show Positive Results -- Update investment picks
2013/10/23
By Rory Gallivan LONDON--Drug company GlaxoSmithKline PLC (GSK.LN) said Wednesday it has made a new drug application for its asthma treatment fluticasone furoate in the U.S. The application with the Food and Drug Administration is for fluticasone furoate to be used as a once-daily inhaled dry powder treatment of asthma in patients aged 12 years and older.
Sign-up for GlaxoSmithKline Submits US Application for Asthma Treatment investment picks
2014/3/28
By Ian Walker LONDON--GlaxoSmithKline PLC (GSK.LN) is taking full control of its Indonesian Consumer Healthcare business in a deal which includes selling a non-core brand and a manufacturing facility in the country.
Sign-up for GlaxoSmithKline Takes Control of Indonesian Consumer Healthcare Unit investment picks
2013/9/30
LONDON--Pharmaceutical giant GlaxoSmithKline PLC (GSK.LN) said Monday it's selling its thrombosis brands, together with the Notre-Dame de Bondeville manufacturing site, to Aspen Pharmacare Holdings Ltd.
Sign-up for GlaxoSmithKline to Sell Thrombosis Brands, Site for GBP0.7 Billion investment picks
2014/2/14
By Ian Walker LONDON--GlaxoSmithKline PLC (GSK.LN) said Friday it has started a Phase III study to evaluate the efficacy and safety of mepolizumab antibody to treat patients with a rare disease characterized by inflammation in the walls of small blood vessels.
Sign-up for GlaxoSmithKline to Start Phase III Trials of Mepolizumab investment picks
RESEARCH TRIANGLE PARK, N.C. , Sept.
Sign-up for GlaxoSmithKline, Community Care of North Carolina harness "small data" to improve patient care and reduce health care costs investment picks
By Ed Ballard GlaxoSmithKline PLC (GSK.LN) and Theravance Inc. (THRX) said Wednesday that the U.S. Food and Drug Administration approved a drug developed by the two companies for the treatment of people with chronic obstructive pulmonary disease.
Sign-up for GlaxoSmithKline, Theravance Get FDA Approval For Lung Disease Drug investment picks
By Ian Walker LONDON--Pharmaceutical giant GlaxoSmithKline PLC (GSK.LN) and U.S. drug developer Theravance Inc. (THRX) said Monday they have received marketing approval from the European Commission for their jointly-developed asthma treatment, Relvar Ellipta.
Sign-up for GlaxoSmithKline, Theravance: Relvar Ellipta Gets EU OK for Asthma Treatment investment picks
2014/3/26
By Rory Gallivan LONDON--Drug group GlaxoSmithKline PLC (GSK.LN) Wednesday said the European Commission has granted marketing authorization for its once-weekly diabetes treatment Eperzan.
Sign-up for GlaxoSmithKline: EU Grants Marketing Approval for Diabetes Drug Eperzan investment picks
By Ed Ballard LONDON--U.K. drug company GlaxoSmithKline PLC (GSK.LN) and Theravance Inc. (THRX) Thursday said a European Union agency recommended that their new treatment for lung disease be approved for sale.
Sign-up for GlaxoSmithKline: European Medicines Agency Recommends Anoro investment picks
LONDON--GlaxoSmithKline PLC (GSK.LN) Friday said the first of its phase 3 studies investigating the combination of Tafinlar and Mekinist in melanoma patients met its primary endpoint of progression-free survival.
Sign-up for GlaxoSmithKline: Phase 3 Melanoma Study Meets Primary Endpoint investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Glaxo Withdraws European Application for Melanoma Treatment to GlaxoSmithKline: Phase 3 Melanoma Study Meets Primary Endpoint
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity